EL7.AI
StocksMedium•16 November 2026•
3 min read

MapLight Reports Quarterly Loss of $0.97 Per Share as Net Loss Rises to $51.6 Million

Key Facts

1Third-quarter 2026 loss per share was $0.97, basic and diluted.
2Quarterly net loss rose to $51.6 million from $29.4 million a year earlier.
3Cash, cash equivalents and investments totaled $463.4 million as of Sept. 30, which the company said would fund development of ML-007C-MA through 2028.
4Research and development expenses rose to $44.2 million from $27.1 million in the third quarter of 2025.
5The company completed a $150 million private placement in August 2026.

MapLight Therapeutics reported third-quarter 2026 net loss per share of $0.97, basic and diluted, as net loss rose to $51.6 million from $29.4 million in the same period of 2025. The company reported the figures in its results statement filed with the U.S. Securities and Exchange Commission. The wider loss reflects increased spending on the development of drug candidates and related operations during the quarter. MapLight is focusing its resources on ML-007C-MA, its drug program that it plans to advance into later-stage registration trials.

Research and development expenses were $44.2 million in the third quarter, compared with $27.1 million a year earlier. The company attributed the increase mainly to continued progress on drug candidates and higher personnel-related expenses. Those expenses included a $5.8 million increase in stock-based compensation between the periods. General and administrative expenses also rose to $11.1 million from $4.4 million in the third quarter of 2025. The company said the increase was related to personnel expenses, including an additional $4.3 million in stock-based compensation, as well as higher professional fees and other expenses.

The increase in losses extended to results for the first nine months of the year: the company recorded a net loss of $172.476 million through Sept. 30, 2026, compared with $81.604 million in the same period of 2025. On funding, cash, cash equivalents and investments totaled $463.4 million as of Sept. 30. Based on its current operating plans and assumptions, MapLight said this balance would fund continued development of ML-007C-MA through 2028. The company completed a $150 million private placement in August 2026, with participation from new and existing institutional investors. It said the proceeds are primarily intended to support the program, including the Zephyr-2 and Vista trials.

In schizophrenia, MapLight said its Phase 2 Zephyr trial met its primary endpoint, with the 210/3 mg twice-daily dose showing a statistically significant reduction that the company described as clinically meaningful in the total Positive and Negative Syndrome Scale score compared with placebo at Week 5. It also reported improvement on a prespecified cognitive measure among participants who had cognitive impairment at the start of the study. The company also recorded significant differences on secondary measures, including the Clinical Global Impression-Severity scale and the PANSS positive factor. Chief Executive Chris Kroeger said the company is focused on advancing ML-007C-MA into an additional registration trial following the Zephyr results. He added that the trial results and tolerability profile support advancing toward the planned Phase 3 trial.

Based on the Phase 2 results, the company has begun preparation activities for the planned Phase 3 Zephyr-2 trial and intends to discuss the regulatory path with the U.S. Food and Drug Administration at an end-of-Phase 2 meeting. The statement lists topline results expected in 2028 in its detailed description of the trial. In its program for psychosis associated with Alzheimer’s disease, the company said enrollment is continuing in the Phase 2 Vista trial, a randomized, double-blind, placebo-controlled study targeting approximately 300 participants. MapLight says ML-007C-MA has Fast Track designation from the U.S. agency for this program. The company also announced that it will halt significant additional investment in its preclinical and discovery programs after near-term milestones and will not advance them into clinical development under its current operating plan, focusing resources on ML-007C-MA.

Open on chart